Atossa Therapeutics, Inc.
ATOS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $14 | $17 | $15 | $9 |
| G&A Expenses | $14 | $14 | $13 | $11 |
| SG&A Expenses | $14 | $14 | $13 | $11 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $28 | $31 | $28 | $21 |
| Operating Income | -$28 | -$31 | -$28 | -$21 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $2 | $1 | $1 | -$0 |
| Pre-Tax Income | -$26 | -$30 | -$27 | -$21 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$26 | -$30 | -$27 | -$21 |
| % Margin | – | – | – | – |
| EPS | -0.2 | -0.24 | -0.21 | -0.18 |
| % Growth | 16.7% | -14.3% | -16.7% | – |
| EPS Diluted | -0.2 | -0.24 | -0.21 | -0.18 |
| Weighted Avg Shares Out | 126 | 126 | 127 | 117 |
| Weighted Avg Shares Out Dil | 126 | 126 | 127 | 117 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4 | $4 | $1 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$28 | -$31 | -$28 | -$20 |
| % Margin | – | – | – | – |